J., Kurita, T., & Bulun, S
GLP-1 medications are FDA-approved for weight management in people without diabetes who have a BMI of 30+ or BMI of 27+ with weight-related health conditions
Potential Benefits & Observed Effects Documented effects from research literature and clinical observations
In the LEADER study with liraglutide, in patients with CKD stage 3, this cardiovascular benefit proved to be greater.58 Although the cardiovascular safety studies were not powered to detect differences in individual components of MACE, some differences between studies were seen in these individual components
It is the recommended diluent for reconstitution of lyophilized peptide research compounds including GLP-3, MOTS-C, BPC-157, TB-500, Tesamorelin, and all blended formulations